Some countries have demonstrated a decreasing and recently stabilising trend in PCa mortality in the last decade, which is largely owed to the adoption of advanced interventional therapy and recalibration of prostate-specific antigen (PSA) testing recommendations [3,4,5]. Here, KLK3 is linked to posterior cortical atrophy.